These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 3907278)

  • 21. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
    Buckley PF
    Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose.
    Kistrup K; Gerlach J; Aaes-Jørgensen T; Larsen NE
    Psychopharmacology (Berl); 1991; 105(1):42-8. PubMed ID: 1745710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pipotiazine palmitate: an evaluation of a new long acting intramuscular antipsychotic agent in severely ill schizophrenic patients.
    Gallant DM; Mielke D; Bishop G; Oelsner T; Guerrero-Figueroa R
    Dis Nerv Syst; 1975 Apr; 36(4):193-6. PubMed ID: 1090427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic implications of different oil vehicles used in depot neuroleptic treatment.
    Knudsen P; Hansen LB; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():7-10. PubMed ID: 3865501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Results of treatment of schizophrenic and schizoaffective patients with sulpiride (Eglonyl Alkaloid) in comparison with perphenazine (Perfenazin Spofa)].
    Svestka J; Rysánek R; Náhunek K; Cesková E
    Cesk Psychiatr; 1990 Jun; 86(3):145-56. PubMed ID: 2225184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Perphenazine enanthate. Results of a 1-year open multicenter study].
    Baruch P; Brion S; Broussolle P; Gayral LF; Ropert R; Volmat R; Porot M
    Encephale; 1989; 15(5):449-55. PubMed ID: 2686965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial.
    Lepola U; Koskinen T; Rimón R; Salo H; Gordin A
    Acta Psychiatr Scand; 1989 Jul; 80(1):92-6. PubMed ID: 2669445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
    Altamura AC; Mauri MC; Girardi T; Panetta B
    Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Study of the clinical effects of sulpiride and perphenazine in 82 schizophrenic patients by the double blind method].
    Asada S; Ishimaru T; Kubo S; Kodama H; Masuda K
    Encephale; 1976; 2(1):73-83. PubMed ID: 770152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-blind comparison of bromperidol and perphenazine.
    Woggon B; Angst J
    Int Pharmacopsychiatry; 1978; 13(3):165-76. PubMed ID: 355182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Dose-effect relations. Doubleblind study on two different doses of pimozide (author's transl)].
    Fleischhauer J
    Arzneimittelforschung; 1978; 28(9):1491-2. PubMed ID: 582541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of efficacy of a new butyrophenone derivative, timiperone and perphenazine in schizophrenia by a multicentre controlled study.
    Takahashi R; Inanaga K; Samejima K; Sarai K; Asada S; Otsuki S; Nakano S
    J Int Med Res; 1982; 10(4):257-67. PubMed ID: 6126413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacology, pharmacokinetics and clinical development of haloperidol decanoate.
    Gelders YG
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():1-11. PubMed ID: 3559159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Results of a double blind study with bromperidol and perphenazine].
    Woggon B
    Int Pharmacopsychiatry; 1978; 13 Suppl 1():62-71. PubMed ID: 35481
    [No Abstract]   [Full Text] [Related]  

  • 37. [Social integration of long-term paraphrenic patients with low-dose depot neuroleptic medication].
    Lesch OM; Dietzel-Rogan M; Musalek M; Rajna P; Rustembegovich A; Schjerve M; Walter H
    Psychiatr Prax; 1985 Mar; 12(2):63-8. PubMed ID: 3887443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perphenazine.
    Anand R; Geffen Y; Vasile D; Dan I
    Clin Neuropharmacol; 2010; 33(6):297-302. PubMed ID: 20921890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial.
    Fruensgaard K; Wollenberg J; Hansen KM; Fensbo C; Sihm F
    Curr Med Res Opin; 1978; 5(8):601-7. PubMed ID: 361345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship between perphenazine plasma levels and clinical response in acute schizophrenia.
    Omérov M; Wistedt B; Bolvig-Hansen L; Larsen NE
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(1-2):159-66. PubMed ID: 2664884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.